<https://rdf.molmedb.upol.cz/reference/ref3610> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM497546.1>,
		<https://identifiers.org/molmedb/MM497547.1>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acs.jmedchem.1c00437"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method33>,
		<https://identifiers.org/molmedb/MM497546>;
	<http://purl.org/ontology/bibo/pmid> "34191513"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/bibliographicCitation> "Trout RE, Zulli A, Mesaros E, Jackson RW, Boyd S, Liu B, Hamrick J, Daigle D, Chatwin CL, John K, McLaughlin L, Cusick SM, Weiss WJ, Pulse ME, Pevear DC, Moeck G, Xerri L, Burns CJ.: Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes. J Med Chem, Volume 64 (14), 2021"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM497547>,
		<https://rdf.molmedb.upol.cz/interaction/membrane21> .
<https://rdf.molmedb.upol.cz/interaction/int1025309> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3610> .
<https://rdf.molmedb.upol.cz/interaction/int1025311> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3610> .
<https://rdf.molmedb.upol.cz/interaction/int1025312> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3610> .
<https://rdf.molmedb.upol.cz/interaction/int1025310> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3610> .